advertisement
Huang W 33
Showing records 1 to 25 | Display all abstracts from Huang W109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Liao C
British Journal of Ophthalmology 2024; 108: 366-371
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Liao J
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109865 Influence of Pilocarpine Eyedrops on the Ocular Biometric Parameters and Intraocular Lens Power Calculation
Gao R
Journal of Ophthalmology 2023; 2023: 7680659
109540 Metabolomic phenotyping of obesity for profiling cardiovascular and ocular diseases
Zhong P
Journal of translational medicine 2023; 21: 384
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Peng B
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109540 Metabolomic phenotyping of obesity for profiling cardiovascular and ocular diseases
Tan S
Journal of translational medicine 2023; 21: 384
109865 Influence of Pilocarpine Eyedrops on the Ocular Biometric Parameters and Intraocular Lens Power Calculation
Liu J
Journal of Ophthalmology 2023; 2023: 7680659
109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Quigley H
British Journal of Ophthalmology 2024; 108: 366-371
109540 Metabolomic phenotyping of obesity for profiling cardiovascular and ocular diseases
Zhu Z
Journal of translational medicine 2023; 21: 384
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Huang G
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Jiang Y
British Journal of Ophthalmology 2024; 108: 366-371
109865 Influence of Pilocarpine Eyedrops on the Ocular Biometric Parameters and Intraocular Lens Power Calculation
Zhou X; Huang L
Journal of Ophthalmology 2023; 2023: 7680659
109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Huang S
British Journal of Ophthalmology 2024; 108: 366-371
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Diao C
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109540 Metabolomic phenotyping of obesity for profiling cardiovascular and ocular diseases
Bulloch G; Long E
Journal of translational medicine 2023; 21: 384
109865 Influence of Pilocarpine Eyedrops on the Ocular Biometric Parameters and Intraocular Lens Power Calculation
Huang W
Journal of Ophthalmology 2023; 2023: 7680659
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Qin Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Huang W
British Journal of Ophthalmology 2024; 108: 366-371
109865 Influence of Pilocarpine Eyedrops on the Ocular Biometric Parameters and Intraocular Lens Power Calculation
Xue Y
Journal of Ophthalmology 2023; 2023: 7680659
109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Friedman D
British Journal of Ophthalmology 2024; 108: 366-371
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Hong Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109540 Metabolomic phenotyping of obesity for profiling cardiovascular and ocular diseases
Huang W
Journal of translational medicine 2023; 21: 384
109745 Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation
Lin J
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2023; 165: 115052
109422 Iris volume change with physiologic mydriasis to identify development of angle closure: the Zhongshan Angle Closure Prevention Trial
Foster PJ
British Journal of Ophthalmology 2024; 108: 366-371
109865 Influence of Pilocarpine Eyedrops on the Ocular Biometric Parameters and Intraocular Lens Power Calculation
Wang F
Journal of Ophthalmology 2023; 2023: 7680659
